Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.87 | N/A | -77.55% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.87 | N/A | -77.55% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook without providing specific future guidance. They emphasized their commitment to advancing clinical trials.
Management did not provide specific guidance for future quarters.
The company is focusing on its ongoing clinical trials.
Protagonist Therapeutics reported a significant miss on EPS, which contributed to a slight decline in stock price by 0.58%. The lack of revenue data and absence of guidance may raise concerns among investors about the company's future performance. The focus on clinical trials suggests that management is prioritizing long-term growth over short-term financial metrics.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WOODWARD INC
Nov 14, 2016